

Roberta Bona

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6810247/publications.pdf>

Version: 2024-02-01

47
papers

1,008
citations

361388

20
h-index

454934

30
g-index

50
all docs

50
docs citations

50
times ranked

1330
citing authors

#	ARTICLE	IF	CITATIONS
1	Successful Immunization with a Single Injection of Non-integrating Lentiviral Vector. <i>Molecular Therapy</i> , 2007, 15, 1716-1723.	8.2	79
2	Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. <i>Vaccine</i> , 2004, 22, 3258-3269.	3.8	70
3	TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells. <i>Oncogene</i> , 2015, 34, 5163-5174.	5.9	69
4	Multicolor Bioluminescence Boosts Malaria Research: Quantitative Dual-Color Assay and Single-Cell Imaging in <i>Plasmodium falciparum</i> Parasites. <i>Analytical Chemistry</i> , 2014, 86, 8814-8821.	6.5	54
5	Development and use of SIV-based Integrase defective lentiviral vector for immunization. <i>Vaccine</i> , 2009, 27, 4622-4629.	3.8	41
6	<i>gag</i> , <i>vif</i> , and <i>nef</i> Genes Contribute to the Homologous Viral Interference Induced by a Nonproducer Human Immunodeficiency Virus Type 1 (HIV-1) Variant: Identification of Novel HIV-1-Inhibiting Viral Protein Mutants. <i>Journal of Virology</i> , 1998, 72, 4308-4319.	3.4	40
7	HIV-1 Tat-Based Vaccines: From Basic Science to Clinical Trials. <i>DNA and Cell Biology</i> , 2002, 21, 599-610.	1.9	35
8	Evaluation of a Self-Inactivating Lentiviral Vector Expressing Simian Immunodeficiency Virus Gag for Induction of Specific Immune Responses <i>In Vitro</i> and <i>In Vivo</i> . <i>Viral Immunology</i> , 2006, 19, 690-701.	1.3	35
9	Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation. <i>Retrovirology</i> , 2015, 12, 4.	2.0	35
10	Virological Consequences of Early Events following Cell-Cell Contact between Human Immunodeficiency Virus Type 1-Infected and Uninfected CD4 + Cells. <i>Journal of Virology</i> , 2008, 82, 7773-7789.	3.4	33
11	<i>cis</i> Expression of the F12 Human Immunodeficiency Virus (HIV) Nef Allele Transforms the Highly Productive NL4-3 HIV Type 1 to a Replication-Defective Strain: Involvement of both Env gp41 and CD4 Intracytoplasmic Tails. <i>Journal of Virology</i> , 2000, 74, 483-492.	3.4	32
12	Transduction of Human Antigen-Presenting Cells with Integrase-Defective Lentiviral Vector Enables Functional Expansion of Primed Antigen-Specific CD8 ⁺ T Cells. <i>Human Gene Therapy</i> , 2010, 21, 1029-1035.	2.7	32
13	Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens. <i>Frontiers in Immunology</i> , 2018, 9, 171.	4.8	31
14	Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 739-750.	3.1	29
15	A high susceptibility to redox imbalance of the transmissible stages of <i>Plasmodium falciparum</i> revealed with a luciferase-based mature gametocyte assay. <i>Molecular Microbiology</i> , 2017, 104, 306-318.	2.5	28
16	Lentivirus-Based Virus-Like Particles as a New Protein Delivery Tool. <i>Methods in Molecular Biology</i> , 2010, 614, 111-124.	0.9	28
17	A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1) HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice. <i>Journal of General Virology</i> , 2006, 87, 1625-1634.	2.9	26
18	Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir with and without Maraviroc Coadministration. <i>Annals of Pharmacotherapy</i> , 2010, 44, 838-843.	1.9	26

#	ARTICLE	IF	CITATIONS
19	Human Immunodeficiency Virus (HIV)-Resistant CD4+ UT-7 Megakaryocytic Human Cell Line Becomes Highly HIV-1 and HIV-2 Susceptible Upon CXCR4 Transfection: Induction of Cell Differentiation by HIV-1 Infection. <i>Blood</i> , 1997, 89, 2670-2678.	1.4	24
20	Nonintegrating Lentiviral Vector-Based Vaccine Efficiently Induces Functional and Persistent CD8+ T Cell Responses in Mice. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-7.	3.0	20
21	Development of a Human Immunodeficiency Virus Vector-Based, Single-Cycle Assay for Evaluation of Anti-Integrase Compounds. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3407-3417.	3.2	18
22	Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells. <i>Vaccine</i> , 2011, 29, 3465-3475.	3.8	17
23	Integrase-Defective Lentiviral Vector Is an Efficient Vaccine Platform for Cancer Immunotherapy. <i>Viruses</i> , 2021, 13, 355.	3.3	17
24	Full expression of transfected nonproducer interfering HIV-1 proviral DNA abrogates susceptibility of human He-La CD4+ cells to HIV. <i>Virology</i> , 1995, 206, 76-84.	2.4	16
25	Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay. <i>Journal of Virological Methods</i> , 2010, 168, 272-276.	2.1	15
26	Antimutagenic activities of naturally occurring polyamines in Chinese hamster ovary cells in vitro. <i>Environmental and Molecular Mutagenesis</i> , 1991, 18, 207-211.	2.2	14
27	Retinoids as modulators of metabolism: their inhibitory effect on cyclophosphamide and 7, 12-dimethylbenz[a]anthracene induced sister chromatid exchanges in a metabolically competent cell line. <i>Mutagenesis</i> , 1990, 5, 397-402.	2.6	12
28	Circular viral DNA detection and junction sequence analysis from PBMC of SHIV-infected cynomolgus monkeys with undetectable virus plasma RNA. <i>Virology</i> , 2004, 324, 531-539.	2.4	12
29	Optimization of Mucosal Responses after Intramuscular Immunization with Integrase Defective Lentiviral Vector. <i>PLoS ONE</i> , 2014, 9, e107377.	2.5	12
30	SAMHD1 phosphorylation and cytoplasmic relocalization after human cytomegalovirus infection limits its antiviral activity. <i>PLoS Pathogens</i> , 2020, 16, e1008855.	4.7	12
31	Anti-HIV Viral Interference Induced by Retroviral Vectors Expressing a Nonproducer HIV-1 Variant. <i>Acta Haematologica</i> , 1996, 95, 199-203.	1.4	10
32	Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. <i>International Journal of STD and AIDS</i> , 2012, 23, 459-463.	1.1	10
33	Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 193-199.	3.0	10
34	Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 418-428.	4.1	10
35	Persistence of azacytidine-induced SCEs and genomic methylation in CHO cells in vitro. <i>Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1990, 245, 211-215.	1.1	8
36	DC contact with HIV-1-infected cells leads to high levels of Env-mediated virion endocytosis coupled with enhanced HIV-1 Ag presentation. <i>European Journal of Immunology</i> , 2009, 39, 404-416.	2.9	7

#	ARTICLE	IF	CITATIONS
37	Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. Journal of Immunological Methods, 2004, 291, 153-163.	1.4	6
38	Human immunodeficiency virus type 1 (HIV-1) protease inhibitors block cell-to-cell HIV-1 endocytosis in dendritic cells. Journal of General Virology, 2009, 90, 2777-2787.	2.9	6
39	Aberrant, noninfectious HIV-1 particles are released by chronically infected human T cells transduced with a retroviral vector expressing an interfering HIV-1 variant. Gene Therapy, 1997, 4, 1085-1092.	4.5	5
40	Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization. Molecular Therapy - Methods and Clinical Development, 2021, 23, 263-275.	4.1	4
41	Human immunodeficiency virus (HIV)-resistant CD4+ UT-7 megakaryocytic human cell line becomes highly HIV-1 and HIV-2 susceptible upon CXCR4 transfection: induction of cell differentiation by HIV-1 infection. Blood, 1997, 89, 2670-8.	1.4	4
42	T cell receptor excision circles (TRECs) analysis during acute intrarectal infection of cynomolgus monkeys with pathogenic chimeric simian human immunodeficiency virus. Virus Research, 2007, 126, 86-95.	2.2	3
43	Effects of Raltegravir on 2-Long Terminal Repeat Circle Junctions in HIV Type 1 Viremic and Aviremic Patients. AIDS Research and Human Retroviruses, 2013, 29, 1365-1369.	1.1	2
44	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. Npj Vaccines, 2022, 7, 44.	6.0	2
45	Murine Granulocyte Macrophage Colony-Stimulating Factor Expressed from a Bicistronic Simian Immunodeficiency Virus-Based Integrase-Defective Lentiviral Vector Does Not Enhance T-Cell Responses in Mice. Viral Immunology, 2014, 27, 512-520.	1.3	1
46	Influence of spermidine on sister chromatid exchanges induced by alkylating agents in mammalian cells in vitro. Anticancer Research, 1989, 9, 1129-32.	1.1	1
47	Antimutagenic activities of naturally occurring polyamines in CHO cells. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1990, 234, 376-377.	0.4	0